FDA data Registry peer set 1 peer

Alternatives to roflumilast

1 same-class SPL records vs roflumilast - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.

View roflumilast → All alternatives

Brand: Daliresp

PDE4 Inhibitor Prescription 1 alternative found

About roflumilast

Roflumilast (Daliresp) helps to reduce flare-ups in people with severe COPD. It is for people who also have chronic bronchitis and a history of COPD flare-ups.

Used for: Roflumilast is used to lower your chances of COPD flare-ups. It is for adults with severe COPD linked to chronic bronchitis. You should have a history of COPD flare-ups to use this medicine.

View full roflumilast profile →

1 PDE4 Inhibitor peers (wide set)

apremilast

Rx

Otezla

Apremilast is used to treat active psoriatic arthritis in adults and children 6 years and older. It also treats plaque psoriasis in adults and children 6 years and older who may use light therapy or other medicines that affect the whole body. Apremilast can also treat oral ulcers caused by Behçet's Disease in adults.

Compare roflumilast vs apremilast side-by-side →

roflumilast vs apremilast · FAERS reaction fields

FAERS top-reaction field "Diarrhoea" shows the widest count spread between roflumilast and apremilast in this extract (23,748-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect roflumilast apremilast
Dyspnoea 1,011 -
Death 730 -
Chronic Obstructive Pulmonary Disease 631 -
Diarrhoea 567 24,315
Nausea 465 21,927
Pneumonia 450 -
Weight Decreased 436 4,955
Headache 404 17,679

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

roflumilast peer mix vs class inventory

Peer mix

0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for PDE4 Inhibitor: 2 drugs.

Frequently Asked Questions

What same-class SPL records sit beside roflumilast? ▼
This registry lists 1 PDE4 Inhibitor medication records beside roflumilast, including apremilast. Grouping is therapeutic-class indexing from openFDA/SPL, not a product recommendation.

Reading a wide PDE4 Inhibitor peer set (1 records)

roflumilast (Daliresp) sits in a wide PDE4 Inhibitor peer set (1 of 1 class peers shown). Labeled indication field for roflumilast: Roflumilast is used to lower your chances of COPD flare-ups.

Top FAERS reaction fields for roflumilast total 5,353 reports across 10 reactions, set beside apremilast. Counts are exposure-weighted submissions, not per-patient risk.

Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full roflumilast profile →

Field note for roflumilast: see also the generic vs brand label guide when reading Daliresp SPL strings.

Read our methodology - how this data is sourced, computed, and verified.